Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul;473(7):2355-61.
doi: 10.1007/s11999-015-4134-z. Epub 2015 Jan 13.

What is the Proportion of Patients With Multiple Hereditary Exostoses Who Undergo Malignant Degeneration?

Affiliations

What is the Proportion of Patients With Multiple Hereditary Exostoses Who Undergo Malignant Degeneration?

Cory M Czajka et al. Clin Orthop Relat Res. 2015 Jul.

Abstract

Background: Multiple hereditary exostoses is an autosomal-dominant skeletal disorder that has a wide-ranging reported risk of malignant degeneration to chondrosarcoma.

Questions/purposes: The aims of our study were to use a large, web-based survey approach to characterize (1) the demographic distribution of patients with multiple hereditary exostoses, (2) the number of surgeries performed related to one's diagnosis of multiple hereditary exostoses, and (3) the proportion of survey respondents who described experiencing malignant degeneration in a large international, heterogeneous cohort of patients with multiple hereditary exostoses.

Methods: An anonymous web-based survey was distributed to several online support groups and social media networks designed to support and educate patients with multiple hereditary exostoses and their families. The survey collected demographic and epidemiologic data on 779 respondents. Data were recorded to assess respondents' disease burden and the rate of malignant degeneration.

Results: Females represented a slightly greater proportion of those with multiple hereditary exostoses who responded (56% female; 419 of 742 patients). Median age for all respondents was 28 years (range, < 1-85 years). Median age for males was 25 years (range, < 1-85 years), while median age for females was 29 years (range, < 1-82 years). The mean age at diagnosis of male and female respondents was in the mid-first decade (5.4 years ± 7.2 years). The mean number of surgeries a patient had undergone was 7.3 (± 7.1 surgeries). The proportion of respondents who experienced malignant transformation was 2.7% (21 of 757 respondents), at a mean age of 28.6 years (± 9.3 years). The most common sites of malignant change from benign exostoses included the pelvis (eight of 21 respondents) and scapula (four of 21 respondents).

Conclusions: In the largest and most geographically diverse study of patients with multiple hereditary exostoses of which we are aware, we found the proportion of patients with multiple hereditary exostoses who have undergone malignant degeneration to be consistent with those reported in prior studies. Our study perhaps more accurately assessed the proportion of patients who undergo malignant transformation of multiple hereditary exostoses. As with prior studies on this topic, the proportion of malignant change may be expected to represent a high-end estimate as recruitment and selection bias likely predisposes for patients with more severe disease, whereas patients with lesser disease may be unaware of their diagnosis. In discussing the sequelae of multiple hereditary exostoses, clinicians perhaps might use this study to offer an unspecific statement of risk of malignant degeneration of multiple hereditary exostoses among the population at large.

Level of evidence: Level IV, prognostic study.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The geographic distribution of applicable respondents to our study survey is shown. Locations included Costa Rica (4), Israel (4), Portugal (4), Italy (3), Mexico (3), Sweden (3), Belgium (2), Germany (2), Guatemala (2), Indonesia (2), Jordan (2), Malta (2), Peru (2), Poland (2) Serbia (2), Algeria (1), Argentina (1), Bulgaria (1), Colombia (1), Finland (1), Haiti (1), India (1), Ireland (1), Japan (1), Netherlands (1), Panama (1), Puerto Rico (1), Romania (1), Russia (1), Singapore (1), South Africa (1), and South Korea (1).
Fig. 2
Fig. 2
The distribution of the number of surgical procedures respondents had as a representation of their disease burden is shown.
Fig. 3
Fig. 3
The anatomic sites of the chondrosarcoma lesions among the 21 respondents who had malignant transformation are shown.

Similar articles

Cited by

References

    1. Altay M, Bayrakci K, Yildiz Y, Erekul S, Saglik Y. Secondary chondrosarcoma in cartilage bone tumors: report of 32 patients. J Orthop Sci. 2007;12:415–423. doi: 10.1007/s00776-007-1152-z. - DOI - PubMed
    1. Cook A, Raskind W, Blanton SH, Pauli RM, Gregg RG, Francomano CA, Puffenberger E, Conrad EU, Schmale G, Schellenberg G, Wijsman E, Hecht JT, Wells D, Wagner MJ. Genetic heterogeneity in families with hereditary multiple exostoses. Am J Hum Genet. 1993;53:71–79. - PMC - PubMed
    1. Gordon SL, Buchanan JR, Ladda RL. Hereditary multiple exostoses: report of a kindred. J Med Genet. 1981;18:428–430. doi: 10.1136/jmg.18.6.428. - DOI - PMC - PubMed
    1. Goud AL, de Lange J, Scholtes VA, Bulstra SK, Hams SJ. Pain, physical and social functioning, and quality of life in individuals with multiple hereditary exostoses in the Netherlands: a national cohort study. J Bone Joint Surg Am. 2012;94:1013–1020. doi: 10.2106/JBJS.K.00406. - DOI - PubMed
    1. Hattori H, Asagai Y, Yamamoto K. Sudden onset of saphenous neuropathy associated with hereditary multiple exostoses. J Orthop Sci. 2006;11:405–408. doi: 10.1007/s00776-006-1029-6. - DOI - PubMed